Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Published:2020-08-13 Issue:7 Volume:383 Page:617-629
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

DiNardo Courtney D.¹,Jonas Brian A.¹,Pullarkat Vinod¹,Thirman Michael J.¹,Garcia Jacqueline S.¹,Wei Andrew H.¹,Konopleva Marina¹,Döhner Hartmut¹,Letai Anthony¹,Fenaux Pierre¹,Koller Elizabeth¹,Havelange Violaine¹,Leber Brian¹,Esteve Jordi¹,Wang Jianxiang¹,Pejsa Vlatko¹,Hájek Roman¹,Porkka Kimmo¹,Illés Árpád¹,Lavie David¹,Lemoli Roberto M.¹,Yamamoto Kazuhito¹,Yoon Sung-Soo¹,Jang Jun-Ho¹,Yeh Su-Peng¹,Turgut Mehmet¹,Hong Wan-Jen¹,Zhou Ying¹,Potluri Jalaja¹,Pratz Keith W.¹

Affiliation:

1. From the Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., M.K.); the Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento (B.A.J.), the Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte (V. Pullarkat), and Genentech, South San Francisco (W.-J.H.) —...

Funder

AbbVie

Genentech

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2012971

Cited by 1630 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy;Leukemia Research;2024-11

2. Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia;Leukemia Research;2024-10

3. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia;European Journal of Medicinal Chemistry;2024-10

4. Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy;Biomedicine & Pharmacotherapy;2024-10

5. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML;Blood Advances;2024-09-24